Pharmaceutical Manufacturing Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising R&D investments by Big Pharma

Rising research budgets can increase manufacturing demand when funded medicines advance toward production. GSK plc's total research and development expense increased 18% at actual exchange rates in 2025 versus 2024, or 19% at constant exchange rates.^[1] Novo Nordisk's 2025 R&D reorganization brought manufacturability and supply considerations earlier into drug development. For drug owners, earlier manufacturing input can make process requirements part of development choices instead of a later capacity decision. Bringing those decisions forward can advance demand for process-development work and capacity planning before a medicine reaches commercial production.

Integration of AI-enabled Automation in Legacy Lines

For an existing production line, the commercial test for an AI-enabled retrofit is whether it improves usable medicine output from equipment already in place. An AI-enabled retrofit adds analytics to equipment already installed, so its case rests on the extra specification-conforming output it releases from that equipment. A retrofit that increases specification-conforming output can support additional medicine supply while reducing the need for a comparable addition of physical capacity. Its contribution to manufacturing growth therefore depends on extra conforming units reaching sale. A producer facing added demand therefore measures the retrofit by the conforming units it adds to sellable supply from the existing building.

Biosimilar surge after key patent cliffs

Biosimilar manufacturing gains a concrete demand route when an authorized competitor becomes available to patients. The European Medicines Agency (EMA) reported 41 biosimilar approvals in the European Union in 2025, the highest annual number ever approved. On February 24, 2025, Biocon Biologics, a Biocon Limited subsidiary, launched YESINTEK (ustekinumab-kfce) as one of the first US Stelara biosimilar entrants. Approval activity widens the prospective product pipeline, while a launch establishes a specific medicine requiring supply beyond development work. Commercial readiness can therefore matter alongside biosimilar development progress because the competitive opening is entry into an existing treatment category with a reference medicine already established.

Reshoring & localization of API capacity

Under India's PLI Scheme for Bulk Drugs, production had commenced for 18 active pharmaceutical ingredients (APIs) by March 2026, reducing import dependence. The scheme had also created capacity for 28 APIs, key starting materials and drug intermediates, although 10 had not achieved commercial production by that date. This gap separates APIs that formulators can source from capacity projects awaiting commercial production. For drug formulators, localized production can provide an alternative source of active ingredients rather than merely another prospective plant. The demand effect therefore depends on converting investment into usable supply for finished medicines. Manufacturers able to complete that transition can compete for sourcing relationships that capacity announcements alone cannot secure.

Global drug-pricing pressure & cost-containment

Drug-pricing pressure weakens the revenue available to support manufacturing even when medicines retain a treatment role. Merck & Co reported that global cost-containment efforts pressured pricing and market access in 2025, with government-mandated price reductions in several international markets.^[2] Worldwide combined sales of its Januvia and Janumet fell 31% to USD 429 million in Q2 2026 versus Q2 2025. Merck & Co cited lower US demand and net pricing due to competition, alongside lower Chinese demand and generic competition in other international markets. These mechanisms affect both the value captured per sale and the volume requiring production, making additional capacity an incomplete response. For exposed manufacturers, lower net prices narrow cost recovery while weaker demand reduces the output over which production costs can be spread.

Critical-input supply-chain fragility

Concentrated input supply can constrain production even when finished-dose capacity is available. The European Commission's 2025 assessment found approximately 75% of chemical API production sites outside the EU, notably in India and China. Approximately 21% of the APIs analyzed had no EU production, limiting in-region alternatives if international supply chains are disrupted. Adding downstream capacity alone does not create an alternative source of ingredients. In the United States, Phlow and Fresenius Kabi agreed in February 2026 to supply API and finished doses, respectively, for Epinephrine Injection, USP, to US hospitals, pending approvals for possible 2027 availability. EU formulators therefore retain exposure to international input interruptions, while the conditional US timetable illustrates the lead time involved in establishing a replacement supply chain.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Pharmaceutical Manufacturing Market Segment Analysis

Conventional drugs accounted for a 51.91% share of the pharmaceutical manufacturing market size in 2026. In its 2025 sustainability report, Hikma reported annual US capacity for more than 12 billion finished doses of essential medicines and a portfolio exceeding 800 products, including over 180 sterile injectable medicines. Hikma describes its US portfolio as generic medicines. This combination of dose scale and product breadth gives established manufacturers a production base serving multiple medicine requirements. Hikma's dose scale and portfolio breadth show conventional output depending on keeping many established medicines in continuous supply, which high-volume US plants make possible.

Biologics and biosimilars are the fastest-growing segment, with a projected 10.08% CAGR during 2027-2032. Complex modalities, including bi- and multispecific antibodies and antibody-drug conjugates, contributed more than half of WuXi Biologics' group revenue in H1 2026. Lonza's Integrated Biologics platform recorded 10% constant-currency sales growth in H1 2026 versus H1 2025. WuXi's revenue mix gives complex-modality expertise a direct role in serving its programs, while Lonza's sales result shows expansion in biologics development and manufacturing activity. Complex antibodies and antibody-drug conjugates need molecule-specific process capabilities, so WuXi Biologics' modality mix and Lonza's growth point to specialized suppliers rather than interchangeable capacity.

CMO / CDMO production represented a 59.9% pharmaceutical manufacturing market share in 2026 and is the fastest-growing segment, with a 10.12% CAGR forecast during 2027-2032. WuXi Biologics' manufacturing revenue grew 26.4% in 2025 versus 2024, supported by project progression and the ramp-up of existing projects. Samsung Biologics also secured a manufacturing agreement with a European pharmaceutical company in Q4 2025. That agreement illustrates how drug owners can secure production services through a commercial relationship with a specialist provider. Providers capture the manufacturing opportunity when their capabilities remain relevant as projects move from development toward recurring production.

In-house manufacturing preserves a different form of control over linked production steps. In February 2026, Novo Nordisk reported US in-house Wegovy pill production, with active ingredients made at its Clayton, North Carolina, site and tablets made and packed at its Durham, North Carolina, site. This connects the same drug owner's upstream and finished-dose operations across separate sites. For a product owner, that arrangement can make the coordination of ingredient output, tablet manufacture and packing an internal operational decision. Manufacturing mode determines who coordinates the production chain, with in-house owners setting ingredient and tablet sequencing internally and outsourcing owners placing that coordination with providers.

Tablets were the largest segment, accounting for a 30.88% market share in 2026. In September 2025, Biocon Generics Inc., a wholly owned Biocon Limited subsidiary, inaugurated its Cranbury, New Jersey, oral-solid-dosage facility with annual capacity for 2 billion tablets. Some products had already been commercialized from the site, with several more in the pipeline. Because products were already commercialized from the site and several more were in the pipeline, the 2 billion tablet capacity serves programs already in market and others still to launch.

Injectables are forecast to be the fastest-growing segment, with an 11% CAGR during 2027-2032. Hikma's European Injectables business grew 23% in 2025, with the company linking its regional service to local manufacturing, a short supply chain and a hospital-focused portfolio. In December 2025, the US Food and Drug Administration (FDA) approved Milestone Pharmaceuticals' CARDAMYST (etripamil) nasal spray for adult acute symptomatic paroxysmal supraventricular tachycardia (PSVT). The approval covers self-administration outside emergency departments or other health care settings. A producer choosing between hospital injectables and a self-administered nasal spray is also choosing which treatment setting its formulation can serve.

Batch manufacturing was the largest segment, with a 71.46% market share in 2026. WuXi Biologics reported structural completion and key equipment arrival at its Chengdu microbial drug-substance and drug-product site on April 24, 2026. The site was designed for up to 110 drug-substance batches annually upon completion, with good manufacturing practice (GMP) release expected by the end of 2026. The physical milestone shows a committed buildout, while the prospective batch capacity places production scheduling at the center of the operating model. Batch operators need both the physical facility and the later release milestone to establish a customer-serving production base.

Continuous manufacturing is the fastest-growing segment, with a 10.7% CAGR forecast during 2027-2032. WuXi Biologics, a contract manufacturer, completed the first commercial process performance qualification campaign for 3 single-use bioreactors of 5,000 liters each on its Hangzhou drug-substance line in April 2025. Evotec completed the sale of its biologics site in Toulouse, France, to Sandoz and granted the buyer an indefinite license to Evotec's continuous manufacturing platform, effective December 5, 2025.^[3] Combining site ownership with platform access gives a producer a way to internalize a specific manufacturing model through a completed commercial transaction. Buyers can choose between purchasing manufacturing services on a particular technology platform and owning and licensing the platform itself.

Oncology led with a 29.91% market share in 2026 and is forecast to be the fastest-growing segment, at an 11% CAGR during 2027-2032. Lupin Manufacturing Solutions, a wholly owned Lupin Limited subsidiary and contract manufacturer, announced in November 2025 that it had commissioned a dedicated oncology high-potency API facility in Visakhapatnam, India. The upstream facility was equipped with 20 reactors and designed for batches of 1 to 35 kilograms. IQVIA reported that global oncology prescription medicine sales reached approximately USD 288 billion in 2025, measured at list prices rather than the manufacturer ex-factory net selling prices used for this report's segment values. Lupin's batch range of 1 to 35 kilograms lets the block supply high-potency oncology ingredients for client programs of different sizes, an upstream input to the finished oncology medicines the segment counts.

In diabetes, the commercial issue includes preserving affordable supply when manufacturing priorities change. The World Health Organization (WHO) reported in March 2026 that major suppliers were progressively shifting capacity from older human insulin products toward newer, more profitable treatments. Human insulin was the most affordable option in that account and was included on the WHO Model List of Essential Medicines. That creates a different investment question from adding production for newer treatments, because product availability depends on which medicines retain capacity. The manufacturing opportunity includes maintaining specific affordable insulin products alongside expanding the capabilities required for oncology's forecast growth.

Prescription medicines were the largest segment, holding an 85.67% market share in 2026. In Italy, 66.9% of people assisted by the National Health Service received at least one medicine prescription in 2025, according to the Italian Medicines Agency (AIFA). IQVIA reported global prescription medicine sales of approximately USD 1.7 trillion in 2025, up 10% year on year, at list prices rather than this report's segment basis of manufacturer ex-factory net selling prices. The combination of global spending scale and broad national-system use gives established prescription producers a large supply base to serve, while nonprescription switches create a separate route to additional customers.

Over-the-counter (OTC) medicines are forecast to be the fastest-growing segment, with a 10.9% CAGR during 2027-2032. On May 22, 2026, the FDA approved Galderma's Differin Epiduo Acne Gel, containing adapalene 0.1% and benzoyl peroxide 2.5%, for US OTC use in people ages 12 and older. The prescription-to-OTC switch creates a nonprescription route for a specified formulation and age group. For manufacturers, the production opportunity centers on supplying the formulation covered by that access decision. A targeted switch can expand the accessible customer base while keeping the commercial opening tied to a precisely defined drug and label.

Geography Analysis

North America Pharmaceutical Manufacturing Market

North America held a 36.41% pharmaceutical manufacturing market share in 2026. In September 2025, FUJIFILM Biotechnologies, a contract manufacturing subsidiary of FUJIFILM Corporation, opened the first phase of its planned USD 3.2 billion commercial-scale cell-culture manufacturing site in Holly Springs, North Carolina. The opened phase included 8 mammalian cell-culture bioreactors, each 20,000 liters, with manufacturing scope spanning drug substance and drug product. The site's combination of large-scale cell culture and drug-product capability illustrates a supply base supporting North America's lead, with drug owners able to source both production stages within the region.

Asia-Pacific Pharmaceutical Manufacturing Market

Asia-Pacific is the fastest-growing geography, with a 10.6% CAGR forecast during 2027-2032. In October 2025, Lilly announced an INR 90 billion (USD 1 billion) investment to expand its contract manufacturing operations in Hyderabad, India. Duopharma Biotech increased sterile cephalosporin capacity at its Klang, Malaysia, facility from 600,000 to 800,000 vials per month starting in Q3 2025. The Indian announcement concerns contract-manufacturing expansion, while the Malaysian result shows a completed increase in capacity for a specific medicine category. Regional manufacturers face different expansion choices, with production partnerships and sterile-vial capacity offering separate paths into local manufacturing activity.

In Europe, Gedeon Richter Polska began expanding its medicine plant in Grodzisk Mazowiecki, Poland, in February 2025, estimating about 30% additional company production capacity. In the Middle East and Africa region, Jamjoom Pharma's Egypt facility produced 29 million units in 2025, up from 24.9 million in 2024. In South America, Brazil recorded 6.3 billion medicine packages sold across 14,371 presentations in 2025. Colombia's Gonher announced the opening of its Plant 3 and Plant 4 in Bogotá in June 2025. Gedeon Richter ties its Grodzisk Mazowiecki expansion to medicine security in Poland and Europe, while Brazil's broad presentation range makes supplying a varied medicine assortment a separate test for manufacturers.

Regulatory Framework and Outlook

The comparison covers selected jurisdictions from the perspective of manufacturers establishing nonsterile finished-medicine capacity for local supply. Defined manufacturing-quality frameworks help investors plan while requiring substantive compliance preparation. Administrative changes can alter the route into production separately from the technical work needed to make compliant medicines.

The US easing judgment reflects the July 2026 proposal to register equivalent units at multiple locations making the same drugs under one quality unit and unified pharmaceutical quality system as one establishment. Germany's hardening reflects proposed GMP documentation, computerized-system and AI guidance in the EMA's 2026-2028 program, while India's continuity reflects in-force Schedule M and the November 2025 inspection-preparation request. Brazil's nonsterile continuity rests on RDC 658/2022 general GMP, with Anvisa's sterile-rule review opened in December 2025 and its partial-impact-analysis dialogue announced September 11, 2026 for September 29. South Africa's mandatory September 1, 2026 digital application route retains fees, review and inspections, with renewals and amendments scheduled from October 1 and email submissions permitted for those applications.

Value Chain Stages

The comparison follows drug-substance production through formulation and filling to final labeling and packaging, illustrated by biologic manufacturing services. Conventional tablet production also links ingredient manufacture, dosage-form manufacture and packing, as Novo Nordisk's in-house operations demonstrate. Biocon Generics operates an oral-solid-dosage facility, while WuXi Biologics provides clinical- and commercial-scale biologic drug-substance and drug-product services. Value therefore accrues through both finished-medicine sales and contracted production work, with each operator's earnings depending on the steps it performs.

Integrated tablet production and contracted biologic services place successive stages under different commercial arrangements. An upstream expansion can increase the requirement for dosage-form manufacture and finishing without immediately increasing packaged-medicine output. For an integrated producer, coordinating those steps supports finished-medicine sales, while a service provider can earn additional fees by connecting its substance, filling and packaging work.

Key Opportunities for Market Participants

The comparison examines capital support and supply-resilience openings for finished-medicine manufacturers in the United Kingdom, European Union and United States. These openings connect manufacturing investment with funding availability, critical-medicine resilience and domestic supply development. The commercial distinction is whether an investor can use an active funding route or must develop a project around a prospective policy or supply-chain change. The value of these enablers depends on preparing compliant facilities and securing the ingredients needed for finished-medicine production.

The central opening is the conversion of supply-resilience priorities into manufacturable finished medicines. API Innovation Center identified the lack of a US-based metoprolol API source when announcing planned tablet development in March 2026. A domestic tablet project that also establishes an ingredient source would address the vulnerability where formulation capacity alone cannot.